{
  "data": {
    "indicator": {
      "slug": "ctgov-bsab-phase-3-trials",
      "name": "Phase 3 oncology bispecific antibody trials",
      "definition": "Count of interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) registered as Phase 3 or Phase 2/3, any start date.",
      "unit": "count",
      "scale": "1",
      "default_unit": "count",
      "default_scale": "1"
    },
    "scale": "1",
    "unit": "count",
    "region": {
      "code": "GLOBAL",
      "name": "Global",
      "type": "world"
    },
    "points": [
      {
        "period_start": "2026-09-27",
        "period_label": "as of 27 Sep 2026",
        "value": 160,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_FT5S2411XCK5XSW3EGB3MWNS4T",
        "url": "https://statorigin.org/stat/stat_FT5S2411XCK5XSW3EGB3MWNS4T",
        "source_org": "ClinicalTrials.gov",
        "source": {
          "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
          "org_short_name": "ClinicalTrials.gov",
          "document_title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27",
          "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId",
          "locator": "totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27.",
          "published_date": null
        }
      }
    ],
    "available_regions": [
      "GLOBAL"
    ]
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}